Laryngopharyngeal reflux disease (LPR), an inflammatory condition related to the direct and indirect effects of gastroduodenal content reflux, affects up to 30 percent of otolaryngology patients worldwide. The condition leads to symptoms including chronic throat clearing and cough, excess throat mucus, postnasal drip and vocal changes, which can significantly impact the patient’s quality of life.
Researchers at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) are advancing innovative approaches to decrease tumor recurrence rates in patients with HPV-negative squamous cell carcinoma of the head and neck (SCCHN).
The Division of Otolaryngology-Head and Neck Surgery at Brigham and Women’s Hospital offers expert, individualized care for a range of conditions affecting the ear, nose and throat. Since 2017, Ravindra Uppaluri, MD, PhD, has served as the division chief for the group’s multidisciplinary faculty and staff.
A Phase 2 trial run by the Adult Head and Neck Oncology Program at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) is seeking to reduce the side effects of postoperative therapy for certain head and neck cancer patients, helping them have a better quality of life while maintaining cancer cure rates.
Should allergy medications such as intranasal steroids and oral antihistamines be used to treat isolated otitis media with effusion (OME)? The answer is a resounding no, according to a review of previously collected data published in October’s Current Allergy and Asthma Reports. Rachel E. Roditi, MD, of the Brigham and Women’s Hospital Division of Otolaryngology-Head and Neck Surgery is lead author of the paper.
A duo at Brigham and Women’s Hospital has developed a new intraoperative, image-based guidance system to help surgeons more accurately visualize anatomical structures. The technology uses augmented reality to precisely register operative endoscopy views with preoperative CT or MRI images, allowing for real-time adjustment and fine-tuning based on the operator’s changing visual field.
Clinicians at Brigham and Women’s Hospital are using hypoglossal nerve stimulation (HNS) to treat obstructive sleep apnea (OSA) in patients who struggle to tolerate the first-line therapy, continuous positive airway pressure (CPAP). The Brigham is a leader in using the novel procedure, which involves surgically implanting a device in patients to relieve apnea episodes. HNS offers hope to those with OSA who are intolerant to CPAP.
In 2011, Brigham and Women’s Hospital made headlines as the site of the nation’s first full face transplant. In July 2019, the Brigham set another milestone with the world’s first full face transplant procedure on a black patient and the oldest recipient ever. It was the ninth face transplant at the Brigham and the 15th nationwide.
Oral cancers account for about two percent of all malignancies and 1.2 percent of cancer-associated deaths. If oral cancer is caught early, the five-year survival rate is 82.8 percent. Once the cancer metastasizes, that rate drops to 28 percent.
A collaborative research team at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) has received a grant to study immunotherapy resistance in head and neck cancer. The team is one of a handful to receive a multi-year cancer immunotherapy research grant this year from the National Institutes of Health (NIH) as part of the Cancer Moonshot℠ program.